Ipratropium Bromide Inhalation Solution Rx
Generic Name and Formulations:
Ipratropium bromide 0.02% (500mcg in 2.5mL); for oral inhalation; preservative-free.
Various generic manufacturers
Indications for Ipratropium Bromide Inhalation Solution:
Bronchospasm associated with chronic bronchitis and emphysema.
500mcg orally by nebulization 3–4 times daily; separate doses by 6–8 hours.
Allergy to atropine or its derivatives.
Not for primary treatment of acute attack. Avoid eyes. Narrow-angle glaucoma. GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Caution with other anticholinergics.
Bronchitis, COPD exacerbation, dyspnea, headache, anticholinergic effects; paradoxical bronchospasm, hypersensitivity reactions.
Formerly known under the brand name Atrovent.
HFA (NO); soln (YES)
Inhaler—12.9g (200 inh); inhalation soln—contact supplier
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC